Literature DB >> 3107908

Cytochrome P450, drug metabolizing enzymes and arachidonic acid metabolism in bovine ocular tissues.

M L Schwartzman, J Masferrer, M W Dunn, J C McGiff, N G Abraham.   

Abstract

Little information is available on drug metabolizing enzymes in ocular tissues. We investigated the presence of various cytochrome P450 isozymes by measuring different drug metabolizing enzymes, i.e., aryl hydrocarbon hydroxylase, 7 ethoxycoumarin-o-deethylase and benzphetamine demethylase activities in ciliary body, corneal epithelium and endothelium, retina and retinal pigment epithelium. Our results demonstrate that the ciliary body and the retinal pigment epithelium possess the highest activities of cytochrome P450-dependent monooxygenases in the eye. The highest activity of drug metabolizing enzymes is accompanied by high activity of NADPH cytochrome P450 (C) reductase, an integral component of this enzyme system. Heme oxygenase, a key enzyme for the regulation of heme availability to hemoproteins such as cytochrome P450 also demonstrate high activity in these two ocular tissues. Although the corneal epithelium has a lower activity of drug metabolizing enzymes, it possesses the highest activity of cytochrome P450 species capable of metabolizing arachidonic acid to biologically active compounds, whereas the other ocular tissues possess cyclooxygenase as the main microsomal enzyme that metabolizes arachidonic acid. Whether the observed catalytic activities of drug metabolizing enzymes seen in ocular tissues are associated with major or minor forms of cytochrome P450 is not yet know. However, the specialized location of cytochrome P450 isozymes in ocular tissues suggests a physiological function related to activation of endogenous compounds such as arachidonic acid, in addition to detoxification of drugs.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3107908     DOI: 10.3109/02713688709025223

Source DB:  PubMed          Journal:  Curr Eye Res        ISSN: 0271-3683            Impact factor:   2.424


  7 in total

1.  "Oxidative protector" enzymes in the macular retinal pigment epithelium of aging eyes and eyes with age-related macular degeneration.

Authors:  R N Frank
Journal:  Trans Am Ophthalmol Soc       Date:  1998

Review 2.  Phase I and phase II ocular metabolic activities and the role of metabolism in ophthalmic prodrug and codrug design and delivery.

Authors:  Abeer M Al-Ghananeem; Peter A Crooks
Journal:  Molecules       Date:  2007-03-08       Impact factor: 4.411

Review 3.  Ocular barriers as a double-edged sword: preventing and facilitating drug delivery to the retina.

Authors:  Lixiang Wang; Hui Zhang
Journal:  Drug Deliv Transl Res       Date:  2022-09-21       Impact factor: 5.671

Review 4.  Heme oxygenase-1: a metabolic nike.

Authors:  Barbara Wegiel; Zsuzsanna Nemeth; Matheus Correa-Costa; Andrew C Bulmer; Leo E Otterbein
Journal:  Antioxid Redox Signal       Date:  2014-02-27       Impact factor: 8.401

5.  Induction of heme oxygenase 1 in the retina by intense visible light: suppression by the antioxidant dimethylthiourea.

Authors:  R K Kutty; G Kutty; B Wiggert; G J Chader; R M Darrow; D T Organisciak
Journal:  Proc Natl Acad Sci U S A       Date:  1995-02-14       Impact factor: 11.205

Review 6.  Peptidomimetics Therapeutics for Retinal Disease.

Authors:  Dylan E Parsons; Soo Hyeon Lee; Young Joo Sun; Gabriel Velez; Alexander G Bassuk; Mark Smith; Vinit B Mahajan
Journal:  Biomolecules       Date:  2021-02-24

7.  Discontinuation of the herbal preparation Hypericum perforatum, also known as St John's wort, associated with improved intraocular pressure control in a patient on topical beta-blockers for primary open-angle glaucoma.

Authors:  Magdalena Edington; Thomas Siempis; Donald Montgomery
Journal:  Oman J Ophthalmol       Date:  2018 May-Aug
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.